Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Humoral immune response to influenza vaccine in natalizumab-treated MS patients.
Coping Strategies in Multiple Sclerosis Patients with Frontal Cognitive Disorders.
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits
[Side-effects of glucocorticosteroids in multiple sclerosis: a case report of a patient with global amnesia.]
Multiple sclerosis.
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain.
New technologies for biomarker discovery in multiple sclerosis.
Self-management for people with long-term neurological conditions.
Longitudinal extensive transverse myelitis and optic neuritis: the elements for the diagnosis of neuromyelitis optica.
Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions.
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Yoga for multiple sclerosis: a systematic review and meta-analysis.
Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis.
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.
Pain and multiple sclerosis: pathophysiology and treatment.
Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.
Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system.
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels.
HyperCKemia Related to the Initial and Recurrent Attacks of Neuromyelitis Optica.
Natalizumab in relapsing-remitting multiple sclerosis.
Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.

Pages